A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 18 Jul 2017
Price : $35 *
At a glance
- Drugs Dovitinib (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jan 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.